ATE430935T1 - Nachweis und behandlung von prostatakrebs - Google Patents

Nachweis und behandlung von prostatakrebs

Info

Publication number
ATE430935T1
ATE430935T1 AT02742263T AT02742263T ATE430935T1 AT E430935 T1 ATE430935 T1 AT E430935T1 AT 02742263 T AT02742263 T AT 02742263T AT 02742263 T AT02742263 T AT 02742263T AT E430935 T1 ATE430935 T1 AT E430935T1
Authority
AT
Austria
Prior art keywords
prostate cancer
prostate
detection
treatment
useful
Prior art date
Application number
AT02742263T
Other languages
English (en)
Inventor
John L Magnani
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Application granted granted Critical
Publication of ATE430935T1 publication Critical patent/ATE430935T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02742263T 2001-06-21 2002-06-21 Nachweis und behandlung von prostatakrebs ATE430935T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30025001P 2001-06-21 2001-06-21
PCT/US2002/019851 WO2003000117A2 (en) 2001-06-21 2002-06-21 Detection and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
ATE430935T1 true ATE430935T1 (de) 2009-05-15

Family

ID=23158305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02742263T ATE430935T1 (de) 2001-06-21 2002-06-21 Nachweis und behandlung von prostatakrebs

Country Status (7)

Country Link
US (3) US7135301B2 (de)
EP (1) EP1410022B1 (de)
JP (1) JP2005514585A (de)
AT (1) ATE430935T1 (de)
AU (1) AU2002315411A1 (de)
DE (1) DE60232244D1 (de)
WO (1) WO2003000117A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000117A2 (en) * 2001-06-21 2003-01-03 Glycotech Corporation Detection and treatment of prostate cancer
EP3388086B1 (de) 2007-08-17 2020-10-07 Purdue Research Foundation Psma-bindungsliganden-linker-konjugate und anwendungsverfahren
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CA2825545A1 (en) * 2011-02-24 2012-08-30 Ventana Medical Systems, Inc. Presence of erg gene rearrangements and protein over-expression in low grade pin (lg-pin) in prostate biopsies
ME03486B (de) 2012-10-12 2020-01-20 Medimmune Ltd Pyrrolobenzodiazepine und Konjugate davon
CN108042811A (zh) 2012-11-15 2018-05-18 恩多塞特公司 用于治疗由psma表达细胞引起的疾病的共轭物
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5227160A (en) * 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
JPH11510795A (ja) * 1995-07-14 1999-09-21 グリコテック コーポレイション Ｅｇｆレセプターに関連する癌の処置のための化合物および方法、ならびにｅｇｆレセプターの精製
WO2003000117A2 (en) * 2001-06-21 2003-01-03 Glycotech Corporation Detection and treatment of prostate cancer

Also Published As

Publication number Publication date
AU2002315411A1 (en) 2003-01-08
US20070048809A1 (en) 2007-03-01
US20030096327A1 (en) 2003-05-22
WO2003000117A2 (en) 2003-01-03
US7135301B2 (en) 2006-11-14
DE60232244D1 (de) 2009-06-18
US7727735B2 (en) 2010-06-01
EP1410022A2 (de) 2004-04-21
EP1410022B1 (de) 2009-05-06
EP1410022A4 (de) 2005-08-17
JP2005514585A (ja) 2005-05-19
WO2003000117A3 (en) 2003-11-13
US20110027180A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
ATE430935T1 (de) Nachweis und behandlung von prostatakrebs
Samuel et al. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
ATE497165T1 (de) Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
ATE462973T1 (de) Diagnose und prävention der krebszellinvasion
DE69907152D1 (de) Krebsbehandlung
TR199902828T2 (xx) Lizofosfolipidlerin de�i�mi� konsantrasyonlar� ile birle�tirilmi� kanser belirleme y�ntemi.
DE60123954D1 (de) Vorrichtung zum schützen gegen magnetische und elektrische felder
ATE451477T1 (de) Diagnose und überwachung von hepatozellulärem karzinom
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
DE60032784D1 (de) Markerproteine für prostatakrebs
WO2001065998A3 (en) Methods for the diagnosis and treatment of breast cancer
DE60232069D1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
DE60144027D1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
Park et al. The Suggestion of the clinical application of Sasang Constitutional Diagnosis
HUP0104194A2 (hu) Módszer és készlet foszfatázcélzó toxinok kimutatására
WO2004019875A3 (en) Non-invasive methods to identify agents for treating pain
WO2004073499A3 (en) Diagnosis of primary open angle glaucoma
ATE387913T1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
UA42589A (uk) Спосіб діагностики гомеостазу
UA34212A (uk) Спосіб оцінки результатів лікування хворих на ранні форми сифілісу

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties